Skip to Main Content

Paper Details

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.
Gynecol Oncol Rep
6
2022
Author NameAffiliation
Ronny DrapkinPenn Ovarian Cancer Research Center, Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Ronny DrapkinPenn Ovarian Cancer Research Center, Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Funda Meric-BernstamUniversity of Texas M. D. Anderson Cancer Center
Lewis C CantleyWeill Cornell Medical College
  • 1 - 4

Datasets